Intratumor heterogeneity defines treatment‐resistant HER2+ breast tumors

Targeted therapy for patients with HER2‐positive (HER2+) breast cancer has improved overall survival, but many patients still suffer relapse and death from the disease. Intratumor heterogeneity of both estrogen receptor (ER) and HER2 expression has been proposed to play a key role in treatment failu...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Mol Oncol
Main Authors: Rye, Inga H., Trinh, Anne, Sætersdal, Anna B., Nebdal, Daniel, Lingjærde, Ole Christian, Almendro, Vanessa, Polyak, Kornelia, Børresen‐Dale, Anne‐Lise, Helland, Åslaug, Markowetz, Florian, Russnes, Hege G.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2018
Teme:
Research Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6210052/
https://ncbi.nlm.nih.gov/pubmed/30133130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12375
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki